231 related articles for article (PubMed ID: 24344002)
1. Current role of immunotherapy for the treatment of prostate cancer.
Porfyris O; Kalomoiris P
J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
[TBL] [Abstract][Full Text] [Related]
2. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
Wei XX; Fong L; Small EJ
Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].
Djurhuus SS; Brasso K; Berg KD; Iversen P; Røder MA
Ugeskr Laeger; 2015 May; 177(20):. PubMed ID: 25967247
[TBL] [Abstract][Full Text] [Related]
5. The evolving landscape of immunotherapy in advanced prostate cancer.
Patel VG; Oh WK
Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
[TBL] [Abstract][Full Text] [Related]
6. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
Mulders PF; De Santis M; Powles T; Fizazi K
Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
[TBL] [Abstract][Full Text] [Related]
7. Role of immunotherapy in castration-resistant prostate cancer (CRPC).
Suárez C; Morales-Barrera R; Ramos V; Núñez I; Valverde C; Planas J; Morote J; Maldonado X; Carles J
BJU Int; 2014 Mar; 113(3):367-75. PubMed ID: 23650874
[TBL] [Abstract][Full Text] [Related]
8. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in prostate cancer: challenges and opportunities.
Noguchi M; Koga N; Moriya F; Itoh K
Immunotherapy; 2016; 8(1):69-77. PubMed ID: 26642100
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
Gulley JL; Madan RA; Heery CR
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.
Holko P; Kawalec P
Expert Rev Anticancer Ther; 2014 Jan; 14(1):63-73. PubMed ID: 24224852
[TBL] [Abstract][Full Text] [Related]
12. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
Handy CE; Antonarakis ES
Future Oncol; 2018 Apr; 14(10):907-917. PubMed ID: 29260582
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
Davis K; Wood S; Dill E; Fesko Y; Bitting RL; Harrison MR; Armstrong AJ; Moul JW; George DJ
Clin J Oncol Nurs; 2015 Jun; 19(3):297-303. PubMed ID: 26000580
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.
Reimers MA; Slane KE; Pachynski RK
Curr Urol Rep; 2019 Sep; 20(10):64. PubMed ID: 31482315
[TBL] [Abstract][Full Text] [Related]
15. [Current status and prospects of immunotherapy for castration-resistant prostate cancer].
Yatsuda J; Eto M
Nihon Rinsho; 2014 Dec; 72(12):2174-8. PubMed ID: 25518354
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
Garcia JA; Dreicer R
Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
[TBL] [Abstract][Full Text] [Related]
17. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
[TBL] [Abstract][Full Text] [Related]
18. New approaches to immunotherapy for metastatic castration-resistant prostate cancer.
Subudhi SK
Clin Adv Hematol Oncol; 2019 May; 17(5):283-286. PubMed ID: 31188806
[No Abstract] [Full Text] [Related]
19. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
Dreicer R
Can J Urol; 2014 Apr; 21(2 Supp 1):93-7. PubMed ID: 24775730
[TBL] [Abstract][Full Text] [Related]
20. Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.
George DJ; Nabhan C; DeVries T; Whitmore JB; Gomella LG
Cancer Immunol Res; 2015 Sep; 3(9):1063-9. PubMed ID: 25943532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
